A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

2015109 citationsJournal Articlehybrid Open Access

Authors

Jeong‐Hoon Lee · Seoul National University

Yoon Lee · JW Pharmaceutical (South Korea)

Minjong Lee · Seoul National University

Min Kyu Heo · CreaGen (United States)

Jae–Sung Song · CreaGen (United States)

Kihwan Kim · CreaGen (United States)

Hyunah Lee ·

Abstract

Adjuvant DC vaccine for HCC was safe and well tolerated in phase I/IIa study, and preliminary efficacy data are encouraging to warrant further clinical study in patients with HCC after primary treatments.

Topics & Keywords

Immunotherapy and Immune Responses Hepatitis B Virus Studies Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 113, Issue 12, pp. 1666-1676

DOI: 10.1038/bjc.2015.430

Field-Weighted Citation Impact: 4.43